<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3AQuasi-experiment</id>
	<title>Definition:Quasi-experiment - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3AQuasi-experiment"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Quasi-experiment&amp;action=history"/>
	<updated>2026-05-13T10:04:50Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Quasi-experiment&amp;diff=22058&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Quasi-experiment&amp;diff=22058&amp;oldid=prev"/>
		<updated>2026-03-27T06:02:47Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;🔬 &amp;#039;&amp;#039;&amp;#039;Quasi-experiment&amp;#039;&amp;#039;&amp;#039; is a research design used in insurance and [[Definition:Actuarial science | actuarial science]] to estimate causal effects when random assignment of policyholders, claimants, or other units to treatment and control groups is impractical, unethical, or commercially infeasible. Unlike a fully [[Definition:Randomized controlled trial (RCT) | randomized controlled trial]], a quasi-experiment exploits naturally occurring variation — such as a regulatory change that affected some jurisdictions but not others, a phased rollout of a new [[Definition:Claims management | claims process]], or an eligibility cutoff for a [[Definition:Policyholder | policyholder]] benefit — to construct a credible comparison between groups. In an industry where business constraints and [[Definition:Insurance regulation | regulatory requirements]] make true randomization rare, quasi-experimental methods have become essential to rigorous decision-making.&lt;br /&gt;
&lt;br /&gt;
⚙️ Several families of techniques fall under the quasi-experimental umbrella, each suited to different data structures and institutional settings. [[Definition:Regression discontinuity design (RDD) | Regression discontinuity designs]] leverage sharp eligibility thresholds — for example, evaluating whether policyholders just above versus just below an age-based [[Definition:Premium | premium]] tier boundary exhibit different renewal behavior. [[Definition:Difference-in-differences (DiD) | Difference-in-differences]] approaches compare trends in a group exposed to an intervention (say, a new [[Definition:Fraud detection | fraud-screening]] protocol rolled out in one region) against trends in an unexposed group, netting out common time effects. [[Definition:Propensity score matching (PSM) | Propensity score matching]] constructs synthetic control groups from observational records. Across all these methods, the analyst&amp;#039;s central challenge is to argue convincingly that, absent the intervention, the treated and comparison groups would have evolved similarly — an assumption that must be tested and defended, particularly when results inform [[Definition:Pricing | pricing]] models, [[Definition:Reserving | reserve]] adjustments, or regulatory filings.&lt;br /&gt;
&lt;br /&gt;
💡 The practical value of quasi-experiments in insurance is growing as the industry accumulates richer datasets and faces heightened expectations for evidence-based management. Regulators in markets governed by [[Definition:Solvency II | Solvency II]], the [[Definition:National Association of Insurance Commissioners (NAIC) | NAIC]] framework, and Asia-Pacific supervisory regimes increasingly expect insurers to substantiate claims about the effectiveness of risk-mitigation programs, [[Definition:Underwriting | underwriting]] innovations, and consumer-facing interventions. [[Definition:Insurtech | Insurtech]] firms, too, rely on quasi-experimental evidence to demonstrate to carrier partners that their technology delivers measurable improvements in [[Definition:Loss ratio (L/R) | loss ratios]] or customer retention. Because the cost and disruption of full randomization often exceed what an insurer&amp;#039;s operations can absorb, quasi-experiments occupy a pragmatic middle ground — more rigorous than simple before-and-after comparisons, yet feasible within the commercial realities of running a book of business.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Randomized controlled trial (RCT)]]&lt;br /&gt;
* [[Definition:Propensity score matching (PSM)]]&lt;br /&gt;
* [[Definition:Regression discontinuity design (RDD)]]&lt;br /&gt;
* [[Definition:Difference-in-differences (DiD)]]&lt;br /&gt;
* [[Definition:Selection bias]]&lt;br /&gt;
* [[Definition:Rubin causal model (RCM)]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>